Thiazolidinedione (TZD)

DRUG4 trials

Sponsors

Novartis Pharmaceuticals, Sanofi, Eli Lilly and Company, Janssen Research & Development, LLC

Conditions

Diabetes Mellitus, Type 2Type 2 Diabetes Mellitus

Phase 3

Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin Alone

CompletedNCT00396227

Novartis PharmaceuticalsDiabetes Mellitus, Type 2

Start: 2006-10-31Updated: 2016-11-18

24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine

CompletedNCT00975286

SanofiType 2 Diabetes Mellitus

Start: 2009-10-31End: 2011-08-31Updated: 2016-10-11

A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus

CompletedNCT01468181

Eli Lilly and CompanyType 2 Diabetes Mellitus

Start: 2011-11-30End: 2013-12-31Updated: 2015-01-29

Unknown Phase

Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)

CompletedNCT03249506

Janssen Research & Development, LLCDiabetes Mellitus, Type 2

Start: 2016-05-12End: 2017-11-01Updated: 2017-11-21

Related Papers

Impact of Type 2 Diabetes Duration on the Efficacy and Safety of Add-on Lixisenatide in Asian Individuals Receiving Basal Insulin: A Pooled Analysis.

2023-02-21

Achieving postprandial glucose control with lixisenatide improves glycemic control in patients with type 2 diabetes on basal insulin: a post-hoc analysis of pooled data

Clinical Diabetes and Endocrinology2020-01-143 citations

How many unpublished studies? ClinicalTrials.gov (n = 2614 studies): diabetes | Closed Studies | Interventional Studies | Phase 3, 4 | Search Date: Oct 27, 2014

Figshare2014-01-01